I'm trying something new. I have rejected my morbid fascination with this strange individual (kinda like staring at a traffic accident) and put terryble and all his transparent aliases on ignore. That would include: themanfromkohlrabi, sin-til-zee, backwardpalaver, kinkybooze, 140cataracts etc, etc, etc.
Then, all his posts pile up at the bottom of the page like footnotes, and I emphasize UNREAD footnotes, as they are truly unworthy of a read. You can merely judge the level of his frenzy by how many unread messages pile up at the bottom of the page. I like this as a possible sentiment indicator and might try plotting it against INSM share price.
blasedp31 and all other readers looking for unbiased information about INSM. Do yourself a favor and put terryble and all his transparent aliases on ignore. That would include: themanfromkohlrabi, sin-til-zee, backwardpalaver, kinkybooze, etc, etc, etc.
Then. all his posts pile up at the bottom of the page like footnotes, and I emphasize UNREAD footnotes, because they have long become unworthy of a read. You can merely judge the level of his frenzy by how many unread messages pile up at the bottom of the page. I like this as a sentiment indicator.
You make no money between 8.90 and 31.13 with a straddle at current prices. Not worth it.
So, just asking for a friend, but do you think the actual data will show something entirely different from its statistical analysis and summation? I was reading that just late last year GSK was spearheading a new program that would make available the actual data from clinical trials, apparently something new.
Oh, really. And where did you find this out? Care to share? Schimmer said, "publish data," not "republish data" or "publish an opinion." When you publish data, it is new data. Won't that be exciting?
Piper's Josh Schimmer says that a key opinion leader will soon publish data that will get Insmed's Arikace lung-infection treatment approved based on a primary end-point.
Piper is as confident of Arikace's speedy approval as it was with the prospect of Vanda receiving FDA authorization for its Hetlioz sleep-wake disorder drug - the therapy was approved at the end of January.
Weren't we supposed to hear from some KOL on Arikace prospects according to Piper Jaffray? Maybe this a run up to that event/news.
That's just plain nonsense, terry. This trial was designed in consultation with KOLs, FDA and NIH to find the most reasonable end point. It's ironic you chose this ID, because you really are a quack.
Repost of checksurshorts post:
"Negative at last"
Had posted this before from NTMinfo Dot Org but now seems to be gone:
"Just thought I'd share the fact that, at the end of my trial on Arikace, my sputum tested negative. That's the first time in 4 years I've ever had a negative result! Woohoo!
If things continue to go well with others on the trial, maybe they'll fast track the drug so more people can see if it works for them. So wonderful to have another option when the Big3 don't do the trick. Thanks for all the "congrats"
chgorich, I have run of the mill MAC, but also have Alpha 1 antitrypsin disorder and bronchiectasis. And thanks everyone for the well wishes...I am so excited that, at least for me, it seems like Arikace was able to achieve what the Big 3 couldn't. Can't wait til it's more widely available."
There is a wealth if good information on this site. I strongly recommend reading through all of the posts that contain "Arikace." Several individuals who took part in the trial had strongly recommended for others to get into the trial. It does take some reading between the lines, though, perhaps due to this:
"...I hope that you are accepted. It is a very interesting experience and eye-opening as to the cost and time put into this type of study. They do ask that we not share much of our experience, so as not to influence your experience. That makes real sense to me, because they want each individuals reaction. Good luck."
One point of interest in the "Negative at last" post at the top. That patient recognizes that she only received Arikace during the 2nd half of the trial and then still ended with this result.
In the pIII trial they didn't know what drug they were on. But if 75% of all patients opted to continue in the extension trial, in which all subjects get Arikace, it tells you that Arikace was not performing badly, as far as patient evaluation of outcomes is concerned.
Unfortunately, the way the trial was set up, the head-to-head comparison was not continued. All subjects went onto Arikace, if I am not mistaken.
I think it all rides on a demonstration that Arikace can provide a stabilization or improvement in lung function after 3 cycles of treatment similar to the pII data. As you may remember, the SP was punished when the pIII results were announced. Everyone saw inferior (non-stat-sig) scores compared to TOBI. BUT, the Arikace TREND was superior. If there is some indication that Arikace provides some more durable continuation of this stabiilization or improvement in lung function, I think you will see more confidence in the investment community.
"Large-cap pharmaceutical companies, instead of starting from scratch on a new patent, want an easier and more effective way to replace their lost "cash-cow" revenue. They will look to acquire biotech companies—and their phase 2 or phase 3 drugs."
This could be the biggest year ever for investing in biotech takeover targets—all due to the patent cliff.
Sanofi (NYSE ADR: SNY), Novartis AG (NYSE ADR: NVS), Roche Holding Ltd. (RHHBY), AstraZeneca PLC (NYSE ADR: AZN), and Eli Lilly & Co. (NYSE: LLY)will all be losing more than $6 billion each in annual revenue this year due to expiring patents.
The ideal candidates are small-cap biotech firms whose pipelines include late-stage drug candidates or other promising pharmaceuticals.
With that criteria in mind, here are six small-cap biotech firms on the list of takeover targets to watch in 2014. . .
Biotech Takeover Targets in 2014
(top of the list)
Insmed Inc. (Nasdaq: INSM) primarily develops inhalation therapies for the treatment of lung diseases. Insmed's most notable project is ARIKACE, an inhaled antibiotic for patients suffering from cystic fibrosis and non-tuberculous mycobacteria. Currently, ARIKACE is in phase II trials in the United States and phase III trials in Canada and Europe.
INSM stock has gained an impressive 241% in the last year and currently trades at $19.73. Insmed has a market cap of just $772 million, which also makes it an attractive takeover option for large-cap pharmaceutical companies.
you don't have to play stupid to seem you aren't. you don't have to be obnoxious just because you are.
Consider this terry. In the next couple of days, we can expect an announcement that may confirm the stabilization or improvement in FEV-1 among CF patients beyond 3 cycles of treatment with Arikace that was hinted at in the pIII trial. With these pesky binary outcomes, a one-way bet on single digits may not be wise.